Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Asher A. Chanan-Khan

Hematology Oncology | Hematology | Oncology
4500 San Pablo Rd S, 
Jacksonville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)
4500 San Pablo Rd S, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Asher Chanan-Khan is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Chanan-Khan is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 157 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Enrollment Status: Recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Acalabrutinib, Obinutuzumab
Study Phase: Phase 2
Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy
Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinemia
Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinemia
Enrollment Status: Terminated
Publish Date: September 18, 2025
Intervention Type: Drug, Other
Study Drugs: Ibrutinib, Ixazomib Citrate
Study Phase: Phase 2
Phase I/II Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma
Phase I/II Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Other, Drug
Study Drugs: Dexamethasone, Lenalidomide, R-(-)-Gossypol Acetic Acid
Study Phase: Phase 1
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug, Combination product
Study Phase: Phase 1/Phase 2
Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)
Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)
Enrollment Status: Terminated
Publish Date: January 19, 2021
Intervention Type: Biological, Other, Drug
Study Phase: Phase 2
A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Enrollment Status: Terminated
Publish Date: June 16, 2020
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 10, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

157 Total Publications

Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.
Journal: Med (New York, N.Y.)
Published: April 16, 2025
Similar Doctors
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Sikander Ailawadhi
Hematology Oncology | Hematology | Oncology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Sikander Ailawadhi
Hematology Oncology | Hematology | Oncology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, Mcj Advanced Care At Home, 
Jacksonville, FL 
 (0.1 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sikander Ailawadhi is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Ailawadhi is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ailawadhi is currently accepting new patients.

Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Vivek Roy
Hematology Oncology | Hematology | Oncology
Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Vivek Roy
Hematology Oncology | Hematology | Oncology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vivek Roy is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Roy is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Waldenstrom Macroglobulinemia, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Ricardo D. Parrondo
Hematology Oncology | Hematology | Oncology
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Ricardo D. Parrondo
Hematology Oncology | Hematology | Oncology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ricardo Parrondo is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Parrondo is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Parrondo is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chanan-Khan's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile